Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) – Research analysts at Zacks Research lowered their Q3 2025 earnings per share (EPS) estimates for Agios Pharmaceuticals in a note issued to investors on Wednesday, October 23rd. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings per share of ($1.80) for the quarter, down from their prior forecast of ($1.79). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($4.87) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q4 2025 earnings at ($1.79) EPS, FY2025 earnings at ($6.99) EPS, Q1 2026 earnings at ($1.63) EPS, Q2 2026 earnings at ($1.57) EPS, Q3 2026 earnings at ($1.52) EPS and FY2026 earnings at ($5.95) EPS.
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative return on equity of 47.05% and a negative net margin of 1,165.69%. The business had revenue of $8.60 million for the quarter, compared to analyst estimates of $9.34 million. During the same period in the prior year, the business earned ($1.51) EPS. The company’s revenue for the quarter was up 28.4% on a year-over-year basis.
Get Our Latest Stock Analysis on AGIO
Agios Pharmaceuticals Price Performance
NASDAQ AGIO opened at $45.09 on Friday. The business has a 50 day simple moving average of $44.64 and a 200 day simple moving average of $41.58. Agios Pharmaceuticals has a one year low of $19.80 and a one year high of $53.28. The stock has a market capitalization of $2.56 billion, a P/E ratio of -7.13 and a beta of 0.75.
Insider Activity at Agios Pharmaceuticals
In related news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the transaction, the chief executive officer now owns 78,792 shares of the company’s stock, valued at $3,368,358. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Brian Goff sold 11,091 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the transaction, the chief executive officer now owns 78,792 shares of the company’s stock, valued at $3,368,358. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Cecilia Jones sold 2,542 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.93% of the stock is owned by insiders.
Institutional Trading of Agios Pharmaceuticals
Hedge funds have recently bought and sold shares of the business. Nordea Investment Management AB lifted its holdings in Agios Pharmaceuticals by 13.0% during the first quarter. Nordea Investment Management AB now owns 266,588 shares of the biopharmaceutical company’s stock worth $7,824,000 after acquiring an additional 30,764 shares during the period. Caxton Associates LP bought a new stake in Agios Pharmaceuticals during the first quarter worth $1,087,000. Vanguard Group Inc. lifted its holdings in Agios Pharmaceuticals by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 5,527,438 shares of the biopharmaceutical company’s stock worth $123,096,000 after acquiring an additional 59,851 shares during the period. D. E. Shaw & Co. Inc. lifted its holdings in Agios Pharmaceuticals by 87.3% during the second quarter. D. E. Shaw & Co. Inc. now owns 678,234 shares of the biopharmaceutical company’s stock worth $29,245,000 after acquiring an additional 316,100 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Agios Pharmaceuticals by 23.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock worth $58,861,000 after acquiring an additional 388,381 shares during the period.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Recommended Stories
- Five stocks we like better than Agios Pharmaceuticals
- Dividend Payout Ratio Calculator
- Texas Roadhouse Stock Steering for New Highs This Year
- Are Penny Stocks a Good Fit for Your Portfolio?
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- What is MarketRankā¢? How to Use it
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.